Hormonal
Bariatric surgery is not a guaranteed cure for type 2 diabetes, with significant rates of non-remission (20-40%) and recurrence (up to 50% at 10 years) occurring even after successful weight loss.
Do not assume bariatric surgery is a permanent cure for diabetes. Even with successful weight loss, a significant portion of patients experience diabetes recurrence or require continued medication. Post-surgical care must include ongoing glycemic monitoring and likely continued pharmacotherapy to manage residual metabolic issues.
metabolic/bariatric surgery proved unable to resolve T2D in some 20% to over 40% of diabesity patients within 1 -- 2 years post procedure... T2D was reported to have reoccurred in 50% by 10 years’ follow-up
Why this rating
Based on multiple retrospective analyses, prospective clinical studies, and meta-analyses cited in the text.
Source
Synthetic agents in the context of metabolic/bariatric surgery: expanding the scope and impact of diabetes drug discovery
David R. Janero · Expert Opinion on Drug Discovery · 2014
DOI 10.1517/17460441.2014.876988
More from this paper
- Preoperative glycemic control using synthetic oral hypoglycemic drugs significantly reduces the risk of T2D recurrence after bariatric surgery.Moderate
- GLP-1 receptor agonists may enhance the weight loss and metabolic benefits of adjustable gastric banding (AGB) by mimicking the hormonal effects of more invasive surgeries like Roux-en-Y gastric bypass.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →